Constant leadership changes and erratic decision-making have left the biopharmaceutical industry feeling its chief regulator is as unpredictable as it’s ever been.
WASHINGTON—Dr. Richard Pazdur, a top federal drug regulator, wasn’t on board. He and lawyers from the Department of Health and Human Services objected to a press release from Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results